Gilead Reports Positive Results for Ulcerative Colitis Drug
The drug emvistegrast met its primary clinical response endpoint in a Phase II study of patients with ulcerative colitis.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you believe new oral treatments for chronic bowel conditions will improve your overall quality of life?
Gilead Sciences announced that its experimental oral drug emvistegrast showed promising efficacy in a Phase II study for patients with moderately to severely active ulcerative colitis. Results indicated that 66% of patients on a 200-mg dose achieved clinical response at week 12 compared to 37% in the placebo group.
Why it matters
The study findings support the potential development of emvistegrast as a new treatment option for managing ulcerative colitis. Gilead aims to advance the drug into late-stage testing following these successful outcomes.
The study tested 25-mg, 75-mg, and 200-mg doses of emvistegrast, with the highest dose showing a 31% clinical remission rate versus 8% for placebo. Researchers also observed a 25% Histological Endoscopic Mucosal Improvement rate in the high-dose group.
The players
Gilead Sciences
This American biopharmaceutical company focuses on researching and developing antiviral medications and other innovative therapies.
The details
Researchers randomized patients with moderately to severely active ulcerative colitis to receive daily oral emvistegrast or placebo for 12 weeks. While 36% of emvistegrast patients reported adverse events, four serious incidents occurred among those taking the drug.
Timeline
September 2026: Gilead management teased positive SWIFT study data.
October 19, 2026: Findings were shared at the UEGW meeting.
2027: Gilead plans to initiate a Phase III monotherapy study.
The Big Picture
Comparing current trial data to the 2019 head-to-head study of Entyvio provides a benchmark for evaluating the new therapeutic's market viability. This data represents a shift in Gilead's pipeline as it seeks to enter the competitive landscape of autoimmune disease treatments.
This development suggests that patients with ulcerative colitis may soon have an additional oral treatment option for managing their symptoms. Further clinical trials will be necessary to confirm the safety profile before the drug becomes available to the public.
The takeaway
Emvistegrast demonstrated significant improvement in clinical response and remission rates for patients with ulcerative colitis in this Phase II trial. Patients currently managing the condition should continue monitoring clinical trial updates as the drug progresses toward potential regulatory review.
What happens next
Gilead plans to initiate a Phase III monotherapy study for emvistegrast in 2027.
Further reading
For more context on the latest industry developments, visit the Biotech section.
Live Poll
Do you believe new oral treatments for chronic bowel conditions will improve your overall quality of life?
